bug-ddd
[Top][All Lists]
Advanced

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

Tipster Report issues strong bi


From: Robyn Pritchard
Subject: Tipster Report issues strong bi
Date: Wed, 22 Jun 2005 20:32:57 -0600



 

 

EMERGING GROWTH ALERT

Issue: 1074214
June 2005
Pingchuan Pharmaceutical Inc
Undervalued Special Situation
Symbol: PGCN
52 Week Range 0.15 - 4.00
Shares Float: 25,000,000
Current Price: $4.75 
12 Mo.Target Price $26.00
 Last 5 days gain $3.40

Breaking News Alerts!

Big News Expected  Thursday  Jun  22 
Value should climb quickly!  Be ready for the ride of your life, as you can see so far 

PR Newswire (Tue, Jun 14)
Pingchuan Signs Regional Distribution Contract With Beijing Pingchuan Tianzhi Medical Technology Development Center

EDGAR Online (Mon, May 23)

PINGCHUAN PHARMACEUTICAL INC Files SEC form 10QSB, Quarterly Report

CORPORATE PROFILE :
 Pingchuan Pharmaceutical Inc. (''PGCN'') is a modernized pharmaceutical manufacturer with first-class medical R&D ability, pioneered medicine products, and well-established marketing network. Since its establishment, PGCN has focused its businesses on diabetes medicine and its medical products. The products of PGCN include health care products, varieties of medicine, as well as medical apparatus. Kang Da Glycosuria Capsule is a successful product of PGCN for treating diabetes, which was first developed in 1998 and introduced to the market in 2001. PGCN has well-established marketing network and sale branches, which include about 180,000 retail pharmacies/drugstores across China, agency network in major cities like Beijing, Shanghai, Guangzhou, and Xi'an, special counter sale at drug chain stores in key regions, residence community clinic sale and promotion, as well as internet marketing through the company's website. The marketing network of PGCN covers more than 50% districts of China and exports to US, Japan, Russia, and south-eastern Asia.

About Beijing Pingchuan Tianzhi Medical Technology Development Center

Beijing Pingchuan Tianzhi Medical Technology Development is grouped under Harbin Pingchuan Pharmaceutical Co., Ltd. in Jan. 2000. It is a wholly-owned subsidiary of Harbin Pingchuan Pharmaceutical Company. TIANZHI focuses on dealing with self-produced products, as well as dealing & distributing other medicines, health cares, pharmaceutical apparatuses and international trade businesses TIANZHI was authorized as the exclusive agent for the product of Kangda'an sugar capsule in Beijing area. By the end of 2004, TIANZHI printed out its good result that the total number of medicine bottles sold out was 26,000 and the sales revenue in 2004 was RMB400,000.


PGCN is getting ready to break out. We recommend this as a VERY strong buy.

     

     

     

     

     

     

     

     

     

     

    to $7bn £4bn already raised privately and by governments around the world They also said they wanted to make sure the fund would be spent properly Honouring the dead Mr Clinton and Mr Bush held the news conference at the end of their first day in Thailand The BBC's Chris Hogg in Phuket says it was woundedPolice said that



    reply via email to

    [Prev in Thread] Current Thread [Next in Thread]